Talis Biomedical Corporation Common Stock
TLIS
TLIS was delisted on the 30th of August, 2024.
27 hedge funds and large institutions have $5.6M invested in Talis Biomedical Corporation Common Stock in 2022 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 9 reducing their positions, and 6 closing their positions.
7% less funds holding
Funds holding: 29 → 27 (-2)
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
35% less capital invested
Capital invested by funds: $8.59M → $5.6M (-$2.99M)
44% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$55.6K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$11.3K |
| 3 |
VF
Virtu Financial
New York
|
+$6.29K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$3.93K |
| 5 |
Jane Street
New York
|
+$1.73K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
E
Ergoteles
New York
|
-$37K |
| 2 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$21.9K |
| 3 |
Morgan Stanley
New York
|
-$11.6K |
| 4 |
Millennium Management
New York
|
-$10.7K |
| 5 |
Man Group
London,
United Kingdom
|
-$9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Man Group
London,
United Kingdom
| – | -$9K | -873 | Closed |
|
27
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$7K | -671 | Closed |
|
|
TRCT
28
Tower Research Capital (TRC)
New York
| – | -$3K | -280 | Closed |
|
29
BNP Paribas Financial Markets
Paris,
France
| – | -$382 | -37 | Closed |
|
30
Osaic Holdings
Scottsdale,
Arizona
| – | -$254 | -29 | -22% |
|
31
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$114 | -13 | -62% |
|
32
Simplex Trading
Chicago,
Illinois
| – | +$61 | +7 | +175% |
|
TLIS Hedge Fund Activity: Q4 2022 in Review
27 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Talis Biomedical Corporation Common Stock (TLIS) for Q4 2022, worth a combined $5.6M — down 35% from $8.59M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of TLIS and 4 opened new positions — a net loss of 2 holders — while 9 trimmed existing stakes and 5 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $55.6K. The largest seller was Ergoteles, exiting entirely with an estimated $37K sold.
- 27 institutional investors held Talis Biomedical Corporation Common Stock (TLIS) as of Q4 2022, down from 29 in Q3 2022.
- Funds reported $5.6M of Talis Biomedical Corporation Common Stock stock for Q4 2022, down 35% quarter-over-quarter.
- 4 funds opened new Talis Biomedical Corporation Common Stock positions in Q4 2022 and 6 closed out, a net change of -2 holders.
- The largest Talis Biomedical Corporation Common Stock buyer in Q4 2022 was Citadel Advisors, an estimated $55.6K added.
- The largest Talis Biomedical Corporation Common Stock seller in Q4 2022 was Ergoteles, an estimated $37K sold.
Based on aggregated 13F filings for Q4 2022.